详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Real-world effectiveness and safety of goserelin 10.8-mg depot in Chinese patients with localized or locally advanced prostate cancer

45| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE ◇ 统计源期刊 ◇ CSCD-C ◇ 卓越：重点期刊

作者：

单位： [1]Department of Urology, Meizhou People's Hospital, Meizhou 514089, China. [2]Department of Urology, Jiangsu Province Hospital, Nanjing 210029, China. [3]Department of Urology, Zhongda Hospital Southeast University, Nanjing 210009, China. [4]Translational Research Laboratory for Urology, Ningbo First Hospital, Ningbo 315016, China. [5]Department of Urology, First Affiliated Hospital of Jiaxing, Jiaxing 314050, China. [6]Department of Urology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830091, China. [7]Department of Urology, Baotou Cancer Hospital, Baotou 014016, China. [8]Department of Urology, The People's Hospital of Sichuan Province, Chengdu 610032, China. [9]Department of Urology, Yantai Yuhuangding Hospital, Yantai 264008, China. [10]Department of Urology, Cancer Hospital of The University of Chinese Academy of Sciences, Hangzhou 310022, China. [11]Department of Urology, Zhuhai Hospital Affiliated with Jinan University, Zhuhai 519000, China. [12]Department of Urology,Tongji Hospital,Tongji Medical College,HUST,Wuhan 430032,China. [13]Department of Urology, Qilu Hospital of Shandong University, Jinan 250012, China. [14]Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, China. [15]Department of Urology, Huizhou Third People's Hospital, Huizhou 516002, China. [16]Department of Urology, Jiangmen Central Hospital, Jiangmen 529030, China. [17]Department of Urology, Foshan First People's Hospital, Foshan 528041, China. [18]Department of Urology, Guangzhou Province Traditional Chinese Medical Hospital, Guangzhou 510120, China. [19]Department of Urology, Guangzhou Panyu Central Hospital, Guangzhou 511489, China. [20]Department of Urology, Renmin Hospital of Wuhan University, Wuhan 430064, China. [21]Department of Urology, Hebei Petro China Central Hospital (China National Petroleum Corporation Central Hospital), Langfang 065099, China. [22]Department of Urology, Harbin Medical University Cancer Hospital, Harbin 150086, China. [23]Department of Urology, Shandong Provincial Hospital, Jinan 250014, China. [24]Department of Urology, Shaanxi Provincial People's Hospital, Xi'an 710021, China. [25]Department of Urology, Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan 430032, China. [26]Department of Urology, Peking University Third Hospital, Beijing 100191, China. [27]Department of Urology, Peking University First Hospital, Beijing 100034, China. [28]Department of Urology, Tangdu Hospital, Xi'an 710024, China. [29]Department of Urology, Shijiazhuang City First Hospital, Shijiazhuang 050012, China.

出处：

DOI：

ISSN：

关键词： Goserelin hormone-sensitive luteinizing hormone-releasing hormone prostate cancer China real-world

摘要：

Real-word data on long-acting luteinizing hormone-releasing hormone (LHRH) agonists in Chinese patients with prostate cancer are limited. This study aimed to determine the real-world effectiveness and safety of the LHRH agonist, goserelin, particularly the long-acting 10.8-mg depot formulation, and the follow-up patterns among Chinese prostate cancer patients.This was a multicenter, prospective, observational study in hormone treatment-naïve patients with localized or locally advanced prostate cancer who were prescribed goserelin 10.8-mg depot every 12 weeks or 3.6-mg depot every 4 weeks with or without an anti-androgen. The patients had follow-up evaluations for 26 weeks. The primary outcome was the effectiveness of goserelin in reducing serum testosterone and prostate-specific antigen (PSA) levels. The secondary outcomes included testosterone and PSA levels, attainment of chemical castration (serum testosterone <50 ng/dL), and goserelin safety. The exploratory outcome was the monitoring pattern for serum testosterone and PSA. All analyses were descriptive.Between September 2017 and December 2019, a total of 294 eligible patients received ≥ 1 dose of goserelin; 287 patients (97.6%) were treated with goserelin 10.8-mg depot. At week 24 ± 2, the changes from baseline [standard deviation (95% confidence interval)] in serum testosterone (n = 99) and PSA (n = 131) were -401.0 ng/dL [308.4 ng/dL (-462.5, -339.5 ng/dL)] and -35.4 ng/mL [104.4 ng/mL (-53.5, -17.4 ng/mL)], respectively. Of 112 evaluable patients, 100 (90.2%) achieved a serum testosterone level < 50 ng/dL. Treatment-emergent adverse events (TEAEs) and severe TEAEs occurred in 37.1% and 10.2% of patients, respectively. The mean testing frequency (standard deviation) was 1.6 (1.5) for testosterone and 2.2 (1.6) for PSA.Goserelin 10.8-mg depot effectively achieved and maintained castration and was well-tolerated in Chinese patients with localized and locally advanced prostate cancer.Copyright © 2023 Cancer Biology & Medicine.

语种：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 2 区医学

小类 | 2 区医学：研究与实验 2 区肿瘤学

最新[2025]版：

大类 | 2 区医学

小类 | 2 区医学：研究与实验 2 区肿瘤学

JCR分区：

出版当年[2021]版：

Q2 MEDICINE, RESEARCH & EXPERIMENTAL Q2 ONCOLOGY

最新[2023]版：

Q1 MEDICINE, RESEARCH & EXPERIMENTAL Q1 ONCOLOGY

影响因子： 5.6 最新[2023版] 5.9 最新五年平均 5.347 出版当年[2021版] 6.624 出版当年五年平均 4.248 出版前一年[2020版] 5.5 出版后一年[2022版]

第一作者：

第一作者单位： [1]Department of Urology, Meizhou People's Hospital, Meizhou 514089, China.

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

Real-world effectiveness and safety of goserelin 10.8-mg depot in Chinese patients with localized or locally advanced prostate cancer

文献详情

相关文献